Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Periprocedural Infarction vs. Spontaneous Infarction: Prognostic Significance 

Original title: Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention–Related Myocardial Infarction. Reference: Sergio Leonardi, MD et al. Journal of the American College of Cardiology Vol. 60, No. 22, 2012

Clinical significance of myocardial infarction (MI) associated to coronary angioplasty is a controversial issue worldwide. Most of research on coronary disease includes it as a primary end point weighed against spontaneous MI.

The aim of this study was to compare periprocedural MI vs. spontaneous MI. It analyzed data from 9,087 patients enrolled in two trials that assessed Non ST Segment Elevation Acute Coronary Syndrome (EARLY-ACS and SYNERGY): among these, 893 periprocedural MI and 298 spontaneous MI occurred, and ratios for death at 12 months were compared.

Authors defined periprocedural MI as CK-MB more than 3 times the ULN (upper limit of normal). Adjusted hazard ratios for 1-year death were 1.39 (95% CI: 1.01 to 1.89) for periprocedural MI vs. 5.37 (95% CI: 3.9 to 7.38) for spontaneous MI. In determining the CK-Mb threshold for periprocedural MI to achieve the same prognosis as spontaneous MI, it was observed that elevations of 27 times the ULN were necessary for this to happen.

Conclusion 

The definition of periprocedural infarction used in clinical trials is poorly associated to events, compared to spontaneous infarction.

Editorial Comment:

This study confirms an assumption based on intuition, that cardiac enzymes elevation after angioplasty does not have the same prognosis than Type 1 MI. Further evaluation is required to confirm these results using the new definition of periprocedural MI (a 5 times increase of troponin levels with clinical or electrical signs or ischemia image). Despite the above observations, this study is good news for interventional cardiologists.

Courtesy of María Sol Andres, MD
Hospital Universitario
Fundación Favaloro – Argentina

Dra. María Sol Andrés para SOLACI.ORG

More articles by this author

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...